Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by Jonnyboy85on Dec 03, 2020 6:14pm
142 Views
Post# 32033662

250000 test/$18-$31M estimate was based on only 5 clients?

250000 test/$18-$31M estimate was based on only 5 clients?If I'm reading this right, the initial interest was based on the 5 clients specifically, and of course we have 50+ now. This blows all my estimates out of the water, potentially 10x higher than what I was expecting originally. Any thoughts? This is also pulled from the final prospectus dated Nov 26th 2020



"Upon initiating COVID-19 testing, the Company received initial customer interest for approximately 250,000 COVID-19 Tests from entities such as businesses and municipalities who wished to offer the COVID-19 Tests to their respective employees or citizens."


"During the first six weeks of COVID-19 testing, StageZero performed approximately 5,000 COVID-19 Tests. To the end of October, StageZero had performed approximately 13,000 COVID-19 Tests. The initial orders StageZero entered into for COVID-19 testing was with five (5) client groups; it is now performing tests for approximately fifty (50) client groups and adding more. New groups are being added on an ongoing basis. StageZero anticipates increasing demand for testing over the next several months and through the winter as planned COVID-19 testing commences according to the timetables set by these client groups. The projected growth in COVID-19 testing is occurring and is on pace with StageZero’s expectations with significant growth anticipated on a quarter over quarter basis in order to meet the projected revenue."
<< Previous
Bullboard Posts
Next >>